Eligo Bioscience

Eligo Bioscience was founded in 2014 as a spin-off from MIT and the Rockefeller University based on the discoveries from the Lu and Marraffini labs. The company develops a new generation of biotherapeutics that enable the expression of genetic circuits within target microbial populations and treat a wide-range of bacteria-associated unmet medical needs both in humans and animals. The company has won several international awards, has raised a US$3M seed-round in July 2015 and is currently located at Institut Pasteur in the heart of Paris.

Visit the Eligo Bioscience website

About us

Engage with us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2025 World Economic Forum